Biomarker testing and adjuvant osimertinib use in patients with resectable EGFR-mutated stage IB-IIIA NSCLC: Physician practices, therapy choice, and barriers among US oncologists

被引：0
|
作者：
Aggarwal, Puja
Savill, Kristin M. Zimmerman
Jeune-Smith, Yolaine
Jennings-Zhang, Luke
Bone, Robert
Kelly, Ronan Joseph
Feinberg, Bruce A.
机构：
[1] Cardinal Hlth, Dublin, OH USA
[2] Baylor Univ, Med Ctr, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20007
引用
收藏
页数：1
相关论文
共 21 条
  • [21] NEOADJUVANT IMMUNOTHERAPY IN PATIENTS WITH EARLY-STAGE, HIGH-RISK, ER+/HER2-BREAST CANCER: PHYSICIAN PRACTICES, THERAPY CHOICE, AND BARRIERS AMONG US ONCOLOGISTS
    Aggarwal, P.
    Van Doren, B.
    Jeune-Smith, Y.
    Jennings-Zhang, L.
    Bone, R. N.
    Sadeghi, S.
    Iyengar, N. M.
    Feinberg, B.
    VALUE IN HEALTH, 2024, 27 (12) : S335 - S335
123